Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan; Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, OH, United States.
J Gastrointest Surg. 2024 Jan;28(1):18-25. doi: 10.1016/j.gassur.2023.10.002.
Early-stage intrahepatic cholangiocarcinoma (ICC) is often an indication of curative-intent resection. Although patients with early-stage ICC generally have a better prognosis than individuals with advanced ICC, the incidence and risk factors of recurrence after early-stage ICC remain unclear.
A multi-institutional database was used to identify patients who underwent surgery between 2000 and 2018 for ICC with pathologically confirmed stage I disease. Cox regression analysis was used to identify clinicopathological factors associated with recurrence, and an online prediction model was developed and validated.
Of 430 patients diagnosed with stage I ICC, approximately one-half of patients (n = 221, 51.4%) experienced recurrence after curative-intent resection. Among patients with a recurrence, most (n = 188, 85.1%) experienced it within 12 months. On multivariable analysis, carcinoembryonic antigen (hazard ratio [HR], 1.011; 95% CI, 1.004-1.018), systemic immune-inflammation index (HR, 1.036; 95% CI, 1.019-1.056), no lymph nodes evaluated (HR, 1.851; 95% CI, 1.276-2.683), and tumor size (HR, 1.101; 95% CI, 1.053-1.151) were associated with greater hazards of recurrence. A predictive model that included these weighted risk factors demonstrated excellent prognostic discrimination in the test (12-month recurrence-free survival [RFS]: low risk, 80.1%; intermediate risk, 60.3%; high risk, 37.7%; P = .001) and validation (12-month RFS: low risk, 84.5%; intermediate risk, 63.5%; high risk, 47.1%; P = .036) datasets. The online predictive model was made available at https://ktsahara.shinyapps.io/stageI_icc/.
Patients with stage I ICC without vascular invasion or lymph node metastasis had a relatively high incidence of recurrence. An online tool can risk stratify patients relative to recurrence risk to identify individuals best suited for alternative treatment approaches.
早期肝内胆管癌(ICC)通常是根治性切除的指征。尽管早期 ICC 患者的预后一般优于晚期 ICC 患者,但早期 ICC 后复发的发生率和危险因素仍不清楚。
使用多机构数据库,确定 2000 年至 2018 年间接受病理证实为 I 期疾病的 ICC 手术治疗的患者。采用 Cox 回归分析确定与复发相关的临床病理因素,并开发和验证在线预测模型。
在 430 例诊断为 I 期 ICC 的患者中,约一半(n=221,51.4%)在根治性切除后复发。在复发的患者中,大多数(n=188,85.1%)在 12 个月内复发。多变量分析显示,癌胚抗原(HR,1.011;95%CI,1.004-1.018)、系统免疫炎症指数(HR,1.036;95%CI,1.019-1.056)、未评估的淋巴结(HR,1.851;95%CI,1.276-2.683)和肿瘤大小(HR,1.101;95%CI,1.053-1.151)与复发风险增加相关。包含这些加权风险因素的预测模型在测试(12 个月无复发生存率[RFS]:低危,80.1%;中危,60.3%;高危,37.7%;P=0.001)和验证(12 个月 RFS:低危,84.5%;中危,63.5%;高危,47.1%;P=0.036)数据集中均具有良好的预后判别能力。在线预测模型可在 https://ktsahara.shinyapps.io/stageI_icc/ 获得。
无血管侵犯或淋巴结转移的 I 期 ICC 患者复发率相对较高。在线工具可以对患者的复发风险进行分层,以确定最适合替代治疗方法的个体。